GERMANTOWN, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), today announced continued progression of the Point of Care (POCare) network and infrastructure for the advanced therapeutic services and facilities business through its subsidiary Octomera. The teams have been confirmed as an industrial partner to the University of California Davis, a leading academic institution, following a recent California Institute of Regenerative Medicine (CIRM) grant focused on "Creating a Collaborative California Cell and Gene Therapy Manufacturing Network."
"California leads the way when it comes to looking for impactful advances in medicine. As the field continues to rapidly expand, the need for cell and gene therapy product manufacturing will continue to increase over the next decade, and the state of California needs to be prepared to meet the growing demand from patients for these life-changing therapies," commented Professor Jan Nolta, PhD, Director of the Institute for Regenerative Cures at UC Davis. "We want to take the best parts of traditional solutions and combine them with the next evolution in manufacturing to expand access to clinical trials of potentially lifesaving therapies such as CAR-Ts."
"As part of the two-year, $1.7 million CIRM grant, we will work to standardize a lot of our Good Manufacturing Practice (GMP) manufacturing capabilities across California, while also creating a network to harmonize operations," said Brian Fury, Director of the GMP Facility at UC Davis. "Our goal is to facilitate more accessible patient care production through collaboration with aligned expertise. Being able to expand our service areas while bringing down costs is a necessity for the future of human health."
UC Davis and Orgenesis announced an initial collaboration in 2020, and the relationship has ...